Treace Medical Concepts (TMCI) Cost of Revenue (2020 - 2026)

Treace Medical Concepts' Cost of Revenue history runs 7 years deep, the most recent figure standing at $9.8 million for Q1 2026.

• Quarterly Cost of Revenue fell 8.3% year-over-year to $9.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.1 million (up 0.98% YoY) and the FY2025 annual result came in at $42.9 million, up 4.49% from the prior year.
• Cost of Revenue was $9.8 million for Q1 2026 at Treace Medical Concepts, down from $12.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $13.2 million in Q4 2024 and bottomed at $5.1 million in Q1 2022.
• A 5-year average of $9.1 million and a median of $9.0 million in 2022 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue surged 68.02% — and 2025, when it dropped 8.41%.
• Treace Medical Concepts' Cost of Revenue stood at $9.0 million in 2022, then climbed by 27.14% to $11.5 million in 2023, then increased by 15.36% to $13.2 million in 2024, then retreated by 8.41% to $12.1 million in 2025, then retreated by 19.2% to $9.8 million in 2026.
• Business Quant data shows TMCI's Cost of Revenue at $9.8 million in Q1 2026, $12.1 million in Q4 2025, and $10.5 million in Q3 2025.